Horizon Kinetics Medical ETF
MEDXDividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| December 24, 2025 | $0.41 | 2025-12-23 | 2025-12-23 |
| December 26, 2024 | $0.51 | 2024-12-24 | 2024-12-24 |
| December 29, 2023 | $1.64 | 2023-12-27 | 2023-12-28 |
Dividends Summary
- Consistent Payer: Horizon Kinetics Medical ETF has rewarded shareholders with 3 dividend payments over the past 2 years.
- Total Returned Value: Investors who held MEDX shares during this period received a total of $2.56 per share in dividend income.
- Latest Payout: The most recent dividend of $0.41/share was paid 30 days ago, on December 24, 2025.
- Yield & Schedule: MEDX currently pays dividends yearly with an annual yield of 1.21%.
- Dividend Growth: Since 2023, the dividend payout has decreased by 75.1%, from $1.64 to $0.41.
Company News
On Jun 10, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted 11-0, unanimously recommending the approval of Eli Lilly's (LLY) Alzheimer's disease drug, donanemab.
Eli Lilly and Company (LLY) raised its outlook for 2024 on rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro.
Eli Lilly and Company (LLY) posted robust fourth-quarter 2023 earnings, beating estimates on both the top and bottom lines driven by strong sales of its diabetes and weight-loss treatments.
Eli Lilly (LLY) posted robust third-quarter 2023 earnings results, beating estimates on both the top and bottom lines. Its Mounjaro anti-obesity drug continued its robust performance.
Eli Lilly (LLY) experienced its most significant surge in stock prices in over two decades following the release of an impressive second-quarter 2023 earnings report and an optimistic outlook. ETFs having the largest exposure to the drug maker could be compelling picks to tap the strong growth.
